dc.contributor.author | Vyas, Madhusudan | |
dc.contributor.author | Fagan, Jessica | |
dc.date.accessioned | 2019-01-17T01:21:25Z | |
dc.date.available | 2019-01-17T01:21:25Z | |
dc.date.issued | 2018-09 | |
dc.identifier.uri | https://hdl.handle.net/10652/4460 | |
dc.description.abstract | Theranostics
Lu-177 : timeline
Why Lu-177 is better
Various Lu-177 labelled Radiopharmaceuticals in use
Teaser for the future in New Zealand | en_NZ |
dc.language.iso | en | en_NZ |
dc.rights | All rights reserved | en_NZ |
dc.subject | neuroendocrine tumours (NETs) | en_NZ |
dc.subject | Lu-177 | en_NZ |
dc.subject | Lutetium-177 | en_NZ |
dc.subject | theranostics | en_NZ |
dc.subject | prostate cancer | en_NZ |
dc.subject | radionuclide therapy | en_NZ |
dc.subject | New Zealand | en_NZ |
dc.title | Lu-177: a game-changer | en_NZ |
dc.type | Conference Contribution - Oral Presentation | en_NZ |
dc.date.updated | 2018-12-14T13:30:05Z | |
dc.rights.holder | Authors | en_NZ |
dc.subject.marsden | 1112 Oncology and Carcinogenesis | en_NZ |
dc.subject.marsden | 110313 Nuclear Medicine | |
dc.identifier.bibliographicCitation | Vyas, M. & Fagan, J. (2018, Sepetmber). Lu-177: A Game-changer. Paper presented at the ANZSNM- Annual Branch Meeting-2018, Invercargill,New Zealand. | en_NZ |
unitec.publication.title | ANZSNM- Annual Branch Meeting-2018 | en_NZ |
unitec.conference.title | ANZSNM- Annual Branch Meeting-2018 | en_NZ |
unitec.conference.org | Australian and New Zealand Society of Nuclear Medicine (ANZSNM) | en_NZ |
unitec.conference.location | Invercargill,New Zealand | en_NZ |
unitec.conference.sdate | 2018-09-15 | |
unitec.conference.edate | 2018-09-16 | |
unitec.peerreviewed | yes | en_NZ |
dc.contributor.affiliation | Unitec Institute of Technology | en_NZ |
unitec.identifier.roms | 62837 | en_NZ |
unitec.institution.studyarea | Health Sciences | |